SCD1 Polypeptide Immunity Inducer for Canine and Feline Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for dogs and cats are ineffective, as most tumors are diagnosed at advanced stages, leading to poor treatment outcomes, and there is a lack of therapeutic and prophylactic agents specifically designed for these animals.
Innovation Solution
Development of a novel immunity-inducing agent using a polypeptide derived from dog stearoyl-CoA desaturase 1 (SCD1), which is specifically expressed in various canine and feline cancers, inducing immunocytes and activating cytotoxic T cells to target and regress tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical treatment, radiotherapy, and chemotherapy are used for cancer treatment in dogs and cats, then some cancer cases can be treated, but treatment results have not been improved very much and most tumors are diagnosed at advanced stages leading to poor outcomes
Solution Approach 1:
The patent applies preliminary action by developing immunity-inducing agents that can prevent cancer development and detect cancer antigens at early stages before tumors grow large enough to be clinically apparent. The invention enables early intervention through prophylactic immunotherapy and early-stage diagnostic detection of cancer antigens, allowing treatment before advanced diagnosis occurs
2Adaptability or versatility
If human anti-cancer drugs are administered to dogs and cats, then some treatment can be provided, but the drugs are not specifically designed for these animals and treatment outcomes remain poor
Solution Approach 1:
The patent applies local quality by developing species-specific cancer therapeutic and diagnostic agents tailored to dogs and cats. The invention identifies cancer antigens specific to canine and feline cancers and develops immunity-inducing agents targeted to these species-specific antigens, rather than using general human drugs. This creates locally optimized treatments adapted to the specific biological characteristics of each species
3Reliability
If SCD1 protein is used as a target for cancer therapy, then cell growth suppression and apoptosis induction can be achieved, but there is no report suggesting SCD1 has immunity-inducing activity against cancer cells
Solution Approach 1:
The patent converts the previously unrecognized immunity-inducing capability of SCD1 protein into a beneficial therapeutic mechanism. By discovering that SCD1 protein expressed on cancer cell surfaces can induce immune responses, the invention transforms a mere growth suppression target into a dual-function antigen that both suppresses cancer growth and actively induces immunity against cancer cells
Data Source
AI summary
Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). Further, an in vitro method for preparing an antigen-presenting cell is provided. The method includes the step of contacting the antigen-presenting cell with the at least one polypeptide selected from: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a).